Anti-ADA (full length) polyclonal antibody

Research has pointed to the salience of friendships in predicting abuse in adolescent dating relationships. The current study investigates the perpetration of physical and sexual dating abuse as predicted by individual conditional tolerance for dating abuse within the context of friendship behaviors and group characteristics. Using two waves of the National Survey of Teen Relationships and Intimate Violence (STRiV; N = 511 daters aged 12-18 years), we investigated the effects of baseline individual tolerance for hitting dating partners and friendship factors on perpetration of physical and sexual adolescent dating abuse (ADA) approximately 1 year later. Conditional tolerance for hitting boyfriends was associated with ADA perpetration in the absence of friendship characteristics. Daters who reported recent discussion of a problem with friends and female daters who named all-girl friendship groups were more likely to report ADA perpetration. Close friendships are an avenue for preventing ADA perpetration. Furthermore, ADA perpetration may be reduced by targeting conditional tolerance for violence particularly against male partners within female friendship groups.

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or secondary failure to TNFi due to ineffectiveness of the drug or adverse reactions. Secondary failure and adverse events can be related to the development of anti-drug antibodies (ADA). The earliest studies that reported ADA toward TNFi mainly used drug-sensitive assays. Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-tolerant ADA assays also detect ADA in the presence of drug, which has contributed to the currently reported higher incidence of ADA development. Comprehension and awareness of the assay format used for ADA detection is thus essential to interpret ADA measurements correctly. In addition, a concurrent drug level measurement is informative as it may provide insight in the extent of underestimation of ADA levels and improves understanding the clinical consequences of ADA formation. The clinical effects are dependent on the ratio between the amount of drug that is neutralized by ADA and the amount of unbound drug. Pharmacokinetic modeling might be useful in this context. The ADA response generally gives rise to high affinity IgG antibodies, but this response will differ between patients. Some patients will not reach the phase of affinity maturation while others generate an enduring high titer high affinity IgG response. This response can be transient in some patients, indicating a mechanism of tolerance induction or B-cell anergy. In this review several different aspects of the ADA response toward TNFi will be discussed. It will highlight the ADA assays, characteristics and regulation of the ADA response, impact of immunogenicity on the pharmacokinetics of TNFi, clinical implications of ADA formation, and possible mitigation strategies.